Polycythemia Vera Clinical Trial
Official title:
Etude de l'Observance thérapeutique et Des Effets Secondaires Des Traitements Chez Les Patients traités Pour Polyglobulie de Vaquez et thrombocytémie Essentielle
Patients treated with oral or sub-cutaneous drugs for polycythemia vera or essential thrombocythemia completed an unique paper questionnaire in order to describe their observance, the side effects and their own appreciation of the taken drug.
During one year, all patients with PV or ET followed in our centre, and who took a drug to
treat their MPN, were identified.
The investigators submitted by mail or directly at the consultation a unique questionnaire
containing 25 questions concerning patients characteristics, evaluation of observance,
identification of side effects and own appreciation of the drug.
After completion of the questionnaire, the patients were identified and followed to collect
new data about thrombotic events or phenotypic evolution.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05558696 -
A Study of Bomedemstat (MK-3543) in Participants With Polycythemia Vera (MK-3543-004)
|
Phase 2 | |
| Active, not recruiting |
NCT03289910 -
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
|
Phase 2 | |
| Completed |
NCT02912884 -
Treatment of Polycythaemia Vera and Essential Thrombocythaemia: Influence on the Clot Structure
|
||
| Recruiting |
NCT02897297 -
Myeloproliferative Neoplastic Diseases Observatory From Brest
|
||
| Completed |
NCT01949805 -
Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera
|
Phase 3 | |
| Completed |
NCT00666549 -
Research Tissue Bank
|
||
| Completed |
NCT00241241 -
Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera
|
Phase 2 | |
| Completed |
NCT00052520 -
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05485948 -
A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU
|
Phase 2 | |
| Completed |
NCT01588015 -
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
|
Phase 1 | |
| Completed |
NCT01243944 -
Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)
|
Phase 3 | |
| Recruiting |
NCT05481151 -
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV
|
Phase 3 | |
| Recruiting |
NCT05031897 -
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant
|
Phase 2 | |
| Recruiting |
NCT04116502 -
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
|
Phase 3 | |
| Completed |
NCT01901432 -
A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04262141 -
IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)
|
Phase 2 | |
| Not yet recruiting |
NCT05566535 -
Changes in QoL and Symptoms in Patients With Polycythemia Vera Receiving Ruxo in a Routine Clinical Practice
|
||
| Active, not recruiting |
NCT04057040 -
Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)
|
Phase 2 | |
| Completed |
NCT03907436 -
The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase
|
N/A | |
| Completed |
NCT01981850 -
A Phase 2 Study of RO7490677 In Participants With Myelofibrosis
|
Phase 2 |